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Introduction
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Endothelin 1 (ET1, see table 1 for gene and protein abbreviations) signaling has been
recognized as a driver of osteoblastic metastasis for more than a decade and recent work
points to its having a broader role in bone biology. This review will first outline the ET
signaling pathway and ET metabolism. It will next summarize the role of ET1 signaling in
craniofacial development. Then, it will discuss observations relating ET signaling to
osteoblastic and other osteosclerotic processes in cancer. Finally, it will describe recent work
in our laboratory that points to endothelin signaling as the role of as an upstream mediator of
WNT signaling, promoting bone matrix synthesis and mineralization. It will conclude with a
statement of some remaining gaps in knowledge and proposals for future research. These
will be informed by insights gained from study of ET signaling in the development and
physiology of the cardiovascular system.
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Overview of the ET Signaling Pathway
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The ET system includes 3 small peptide hormones1-3, ET1, ET2, and ET3, 2 G-protein
coupled receptors4,5, EDNRA and EDNRB, and 2 specific converting enzymes6,7, ECE1 and
ECE2. The ETs are synthesized as prepropeptides that are first processed to biologically
inactive, 37-41 amino acid propeptides, commonly known as “big ET’s,” by furin-like
proteases prior to secretion8,9. Following secretion, the big ETs must be converted to their
active forms by proteolytic cleavage in the extracellular space. ECE1 and ECE2, which have
different pH optima (neutral pH optimal for ECE1, acidi pH optimal for ECE2), catalyze ET
activation by cleaving the big ET’s to 21 amino acid active ETs. In addition, big ET’s can be
converted by a variety of other proteases (figures 1 and 2)10-12.
The ET system was discovered in arteries, and it has since been shown that various elements
of the system are expressed in a wide variety of tissues, but expression is not ubiquitous.
Immortalized osteoblasts in culture express ET1, EDNRA, and ECE1, thus having the
capacity for autocrine ET signaling within the lineage13. Conversely, ET2, ET3, EDNRB
and ECE2 are either not detected or expressed at very low levels in these cells13.

ET1 Signaling in Development
VA Author Manuscript

Knockout mice lacking either ET1 or EDNRA have very similar, lethal phenotypes that
result from malformations of the craniofacial bones14,15. Mice die shortly after birth due to
asphyxia, which can be overcome by tracheostomy. They have hypoplastic mandibles,
homeotic transformation of the mandible to a maxillary morphology16,17. There are multiple
defects in other facial and basilar skull bones, and the hyoid bones. Together, these defects
obstruct the airway, leading to the observed lethality. Identical craniofacial defects are
observed in ECE1 knockout mice18.
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In addition to the craniofacial abnormalities, ET1 and EDNRA knockout mice share defects
of the cardiac outflow tract and great vessels15,19. These defects are not fully penetrant, and
include tubular hypoplasia of the aortic arch, absent right subclavian artery and
perimembranous ventricular septal defect. In ECE1 knockout mice, these defects are both
more severe and more penetrant than in the ET1 and EDNRA knockouts18. Box 1 provides
further information about ET signaling in cardiovascular physiology.
The common element linking the craniofacial and cardiovascular anomalies is that the
affected structures are derived from the neural crest. Cranial and cardiac neural crest cells
migrate early in development and express EDNRA15. It is worth noting that knockouts of
ET3 and EDNRB, which are also lethal, affect a different population of neural crest
derivatives. Phenotypes of these mutations include colonic aganglionosis (Hirschsprung’s
disease) and white spotting20,21. As in the case of EDNRA/ET1, EDNRB/ET3 knockouts
have very similar phenotypes. ECE1 knockout animals have all the defects characteristic of
both the EDNRA/ET1 and EDNRB/ET3 knockouts18.
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ET Signaling in Osteoblastic Metastasis
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ET signaling occurs in both mammary and prostate glands, and when it is expressed in
neoplasms arising from those tissues, it promotes osteoblastic metastasis22-26. Osteoblastic
metastasis is very common in prostate cancer and uncommon in breast cancer. In both cases,
lesions feature synthesis of sclerotic, woven bone that is mechanically deficient. We recently
found that ET1 is highly expressed in the setting of osteosclerosis associated with
myelofibrosis27, with very similar features to those encountered in breast and prostate
cancer. Promotion of osteogenesis by ET1 signaling is mediated at least in part by
modulation of WNT signaling. In cultured mouse calvarial osteoblasts, ET1 reduces
transcription and secretion of DKK1, and concomitantly increases bone formation28. In men
with metastatic prostate cancer, EDNRA blockade suppressed progression of bone disease as
measured by bone turnover markers29.
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Human breast cancer cells can convert big ET1 to active ET124,30, suggesting the potential
role of ET1 in bone metastasis in breast cancer. EDNRA blockade reduced osteoblastic
lesions in mice inoculated with ZR-75-1 human breast cancer cells24. Collectively, these
results show that ET1 action via EDNRA mediate bone formation in both breast and prostate
cancer. The bone cells, in turn, secrete factors that can support proliferation of the tumor
cells, such as IGF1, resulting in a vicious cycle of concurrent bone and tumor growth
supported by reciprocal paracrine signaling between tumor cells and osteoblasts.

ET Signaling in Bone Physiology
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In the course of pursuing our long-standing interest in the genetic basis of bone
biomechanical performance, we identified Ece1 as a candidate gene for a pleiotropic
quantitative trait locus (QTL) for bone size, shape, and strength31-35. The QTL increases the
cross-sectional size and ellipticity of the femoral diaphysis, leading to an increase in the
whole bone strength as measured by 3-point bending. This constellation of phenotypes
suggested that the primary process affected by the QTL was bone modeling in response to
mechanical loading (see box 2). Other investigators had determined that our QTL lies within
a genomic region that contributes to load-induced bone modeling36, leading us to
hypothesize that both sets of phenotypes were mediated by the same genes. It is worth
noting that the mouse QTL corresponds to a confirmed human BMD QTL37.
In subsequent experiments, we found that murine osteoblasts grown in tissue culture engage
in autocrine ET1 signaling via EDNRA13 (and Johnson et al., unpublished data). They
express Edn1, Ednra, and Ece1, but not Ednrb. These cells recapitulate maturation of the
osteoblast lineage when placed in medium supplemented with vitamin C and phosphate,
forming mineralized nodules after 2 weeks in mineralization medium. Supplementation of
the medium with big ET1 increases mineralization, which is blocked by pharmacological
inhibition of either ECE1 or EDNRA, treatment with SOST, or by transfection of siRNA
targeting Ece1 message. In addition to promoting mineralization, ET1 treatment reduces
secretion of SOST and DKK1, in spite of increasing transcription of their mRNAs. These
divergent effects on transcription and protein secretion are mediated in part by miR 126-3p,
which is increased by ~120-fold via ET signaling, which targets Sost message. The effects
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of ET1 signaling on mineralization and SOST secretion are mimicked by transfection of a
miR 126-3p expressing lentivirus, while the effects of ET1 signaling blockade are mimicked
by transfection of a lentivirus expressing a miR 126-3p antagonist.
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MiR 126-3p is a critical molecule in angiogenesis38. MiR 126-3p ablated mice have a high
rate of embryonic lethality with impaired blood vessel formation, while the surviving mice
are deficient in the angiogenic response to experimental ischemia39. Important endothelial
cell targets of miR-126-3p include, but are not limited to, mRNAs encoding a pair of VEGF
inhibitors, Pik3r2 and Spred1. It is interesting to note that both in osteoblasts and in
endothelial cells, miR 126-3p acts by releasing repression of critical signaling pathways.

Future Considerations
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Current understanding of ET biology is very uneven. The developmental roles of ET
signaling are relatively well characterized, as is ET signaling within arterial walls. It is also
clear that ET drives osteoblastic metastasis in breast and prostate cancer, but little is known
regarding the role of ET signaling in the normal function of each of these glands, or of the
contribution ET signaling to normal bone physiology. Greater understanding of the ET
signaling pathway’s role in the normal biology of tissues outside the vasculature is therefore
of great importance.
It is important to recall that ET1 signaling is essential in development14,15,18,19, and that the
phenotypes resulting from knockout of Edn1, Ednra, and Ece1 overlap some of those arising
from mutants affecting WNT signaling. Ablation of Ece1, unlike that of either Edn1 or
Ednra, leads to significant mid-gestational in utero lethality due to heart failure, reflecting a
greater severity of cardiac outflow tract abnormalities18. In the chick, ET1 signaling
mediates essential mechanotransductive signals in Purkinje system development40-43.
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However, the situation is more complex. WNT signaling has an unequivocal trophic impact
on cells already committed to the osteoblast lineage; indeed, canonical WNT signaling has
been shown by some investigators to inhibit commitment of mesenchymal stem cells to the
osteoblast lineage44,45. In addition, mice constitutively expressing β-catenin in late stage
osteoblasts and osteocytes have both increased bone volume and osteomalacia46. These
findings demonstrate that normal bone mineralization requires down-regulation of canonical
WNT signaling at late stages of osteoblast maturation, even while elaboration of bone matrix
by less mature cells is promoted.
Down-regulation of SOST, leading to derepression of the WNT pathway has been
demonstrated in an in vivo experimental mechanical loading protocol47. It is unknown at this
point whether ET signaling mediates the SOST response in this setting, thus functioning
upstream of the WNT pathway in mediating mechanotransduction in bone. Our laboratory’s
findings that ET1 signaling reduces SOST expression via miR-126-3p provide a mechanistic
basis for pursuing this line of investigation13 (and Johnson et al., unpublished data). Other
investigators have identified DKK1 as another WNT-related target of ET1 signaling in
cancer28, further supporting the idea that ET signaling is upstream of the WNT pathway in
bone.
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More broadly, little attention has been devoted to identifying common mechanisms of
mechanotransduction in bones and arteries. Both are tubular organs whose function requires
adaptation to highly variable mechanical environments. Bone and vascular biology might
both benefit by further work in this area.
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Finally, osteoblastic metastases arise in other tumors in addition to prostate and breast
cancer. It is worth studying other tumor types to determine whether they share ET1 signaling
as the underlying mechanism.
BOX 1
Physiological ET Signaling in the Cardiovascular System
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The ET system was first discovered in the vasculature and its biology is best understood
in that setting. ET signaling via EDNRB on endothelial cells causes vasodilation and
clearance of ETs from the circulation 48-50. In contrast, signaling via both EDNRA and
EDNRB in smooth muscle cells has potent vasoconstrictive effects 1,51. Endothelial cells
are the primary source of ET1 and have a high density of EDNRB, so autocrine signaling
favors vasodilation and hypotensive responses, while paracrine signaling leads to
hypertensive responses. In experiments we performed using the same mice in which we
identified Ece1 as a candidate gene for bone biomechanical performance, we found that
mice harboring a high-expressing Ece1 allele had larger femoral and arterial crosssections, greater arterial compliance, and lower BP than mice harboring a low-expressing
Ece1 allele 52.
Shear stress plays a critical role in vascular remodeling, both in developmental 53 and
physiological54-56 settings. NO is known to play a central role in mediating vascular
remodeling in pregnancy and its induction by shear stress is well established57-59. In this
setting, NO is produced by NOS3 and the Nos3 gene is induced by EDNRB activation in
endothelial cells49. Insufficient EDNRB function exacerbates inward hypertophic
vascular remodeling by low flow60. Taken together, these findings suggest that ET
signaling via EDNRB could contribute to outward remodeling in response to high shear
stress.
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While osteoblasts and endothelial cells express all the genes necessary for autocrine ET1
signaling, in blood vessels there is a necessary balance between autocrine and paracrine
ET1 signaling. Paracrine signaling contributes to the greater thickness and higher smooth
muscle content of arterial v venous walls. Even though arterial and venous identities are
established prior to the onset of circulation61, mechanical signals reinforce and amplify
those differences 53. It is presently unknown whether specific mechanical environments
lead to differential endothelial cell expression of Edn1 and of Ece1. Should this prove to
be the case, differential regulation of these genes by distinct mechanical environments
could provide a mechanism by which wall stress and shear stress might lead to distinct
adaptive responses.
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BOX 2
The Skeletal Mechanostat and the WNT Pathway
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The ability of bone to alter its size and shape in response to its habitual mechanical
environment is well established. Overloading leads to an increase in long bone crosssectional size, as was demonstrated in elite racquet sport athletes 62. Conversely,
underloading, as occurs in spaceflight, prolonged bed rest, or spinal cord injury leads to
loss of skeletal mass 63-65. The notion that bone mass is physiologically regulated has
been formalized in the mechanostat model of bone modeling 66,67. Briefly stated, the
model holds that bone modeling (change in diameter and/or cross-sectional geometry)
occurs to maintain mechanical strain (fractional change in length) within a narrow
physiological range. Once such physiological equilibrium is reached, bone size and shape
remains stable unless disturbed.
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Widely accepted experimental interventions to allow study of defined skeletal loading
conditions in experimental animals have been developed. Ulnar loading coupled with
dynamic histomorphometry allows the in vivo modeling response to loading to be
measured, using the contralateral, unloaded limb as a control 12. Tail suspension 68 and
sciatic neurectomy 69 both allow study of in vivo unloading. These powerful investigative
tools have been used in genetically engineered mice to identify critical molecules
mediating mechanotransduction.
The canonical WNT signaling pathway is one of the principal mechanisms by which
bone responds to its mechanical environment. Recognition of its central role in bone
biology emerged from the recognition that inactivating and activating mutations of LRP5,
a WNT co-receptor, caused two rare Mendelian conditions, the osteoporosis
pseudoglioma syndrome and hereditary high bone mass, respectively 70-72. Mendelian
high bone mass high bone mass disorders, sclerosteosis and Van Buchem’s disease, arise
as a consequence of mutations in SOST, the gene encoding the WNT antagonist
sclerostin 73,74. Overexpression of the WNT inhibitor DKK1 drives bone resorption in
multiple myeloma75.
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While human disease provided the first clues that WNT signaling is critical in bone
physiology, mechanistic understanding of bone mass regulation has been achieved
through study of mouse models. Experiments featuring ulnar loading demonstrated that
loss of function Lrp5 (mouse homolog of LRP5) mutations lead to decreased loadinduced modeling76,77, while mutations that mimic human high bone mass variants
display increased modeling in response to mechanical loading77-79. These modeling
responses demonstrate that disruption of the WNT pathway affects physiology as well as
development.
SOST is a WNT inhibitor and is produced constitutively by mature osteocytes, but its
expression is decreased in the presence of mechanical loading47. Mice in which Sost (the
mouse gene encoding SOST) has been knocked out display increased bone mass,
mimicking the human sclerosteosis phenotype80,81.

Endocrinol Metab Clin North Am. Author manuscript; available in PMC 2018 March 01.

Kristianto et al.

Page 7

Furthermore, SNPs within or near genes involved in the WNT pathway are associated
with mass and fractures in humans37,82-85. In the case of LRP5, there is evidence from
the Framingham cohort that the association with BMD is exercise dependent86. AntiSOST antibodies are presently being tested as possible drugs to increase bone mass and
prevent fracture87,88.
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•

The endothelin system includes 3 small peptide hormones that are secreted as
inactive precursors, a pair of G-protein coupled receptors, and a pair of
membrane bound, extracellular converting enzymes.

•

Endothelin 1/endothelin receptor A signaling is essential for the development
of the craniofacial skeleton. Knockouts of the Edn1, Ednra, and Ece1 genes
have lethal phenotypes.

•

Endothelin signaling is osteogenic in the setting of prostate and breast cancer.

•

Genetic evidence points to allelic variation of Ece1 as a mediator of bone
biomechanical performance.

•

In vitro experiments indicate that ET signaling derepresses WNT signaling,
and thus may function upstream of WNT in mediating mechanical
homeostasis of skeletal mass.
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The endothelin (ET) system includes 3 small peptide hormones and a pair of G-protein
coupled receptors. All 3 ETs are secreted as biologically inert precursors that must be
activated by proteolytic cleavage after secretion. This reaction can be catalyzed by a pair
of specific, membrane bound extracellular endothelin converting enzymes or by
nonspecific tissue proteases. The ET1/EDNRA axis is essential in development, with
knockout mice for either ET1 or EDNRA displaying a similar phenotype featuring
multiple defects of the craniofacial skeleton and cardiac outflow tract. Prostate and breast
cancers sometimes display osteoblastic metastases driven by high tumor cell expression
of ET1. ET1-driven osteosclerosis may also occur in the setting of myelofibrosis.
Osteoblasts express ET1, EDNRA, and ECE1, and therefore are capable of autocrine ET
signaling. Searches for genes that mediate individual differences in bone biomechanical
performance have identified the gene encoding ECE1 as a candidate. Mechanistic studies
in vitro show that ET signaling in osteoblasts increases matrix synthesis and
mineralization and derepresses WNT signaling, acting in part via the micro-RNA miR
126-3p.
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Figure 1. Schematic representation of endothelin synthesis, secretion, and receptor binding
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The horizontal line represents the cell membrane, with events above the line occurring
intracellularly and those below the line occurring extracellularly. Both the ET receptors and
the ECEs are membrane bound, but their ligand binding/catalytic sites are extracellular. ETA
represents the A type endothelin receptor, encoded by EDNRA in humans and Ednra in
mice. ETb represents the B type endothelin receptor, encoded by EDNRB in humans and
Ednrb in mice. All 3 endothelins are initially synthesized as pre-propeptides, encoded by
EDN1, EDN2, and EDN3 in humans and Edn1, Edn2, and Edn3 in mice. They are processed
to the respective big ETs by furin-like proteases prior to secretion. The big ETs are further
processed to the mature, biologically active ETs by the ECEs or other extracellular
proteases. B type receptors in endothelial cells promote NO synthesis, cell survival, and ET
clearance. Both A type and B type receptors promote smooth muscle cell contraction and
collagen synthesis by fibroblasts.
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Figure 2. Schematic representation of autocrine and paracrine ET1 signaling

In blood vessels, the balance of autocrine and paracrine signaling is important in
determining the biological response to ET signaling. Big ET1 is secreted by endothelial
cells. It can be processed to mature ET1 by membrane-bound ECE1 by the endothelial cells
and signal in an autocrine fashion via either A type or B type receptors on the endothelial
cells. These cells express predominantly B type receptor, thus favoring vasodilatory
responses. Alternatively, mature ET1 (21 amino acids) or big ET1 (38 amino acids) can
diffuse in the extracellular space. Big ET1 can be activated by other tissue proteases and can
signal via ET receptors located on smooth muscle cells, fibroblasts, or other cells present in
the vessel wall or perivascular space. Activation of these cell types by ET1 promotes
vasoconstriction and thickening/stiffening of the media. The activity of ECE1 can alter the
balance of autocrine v paracrine ET1 signaling.
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Genes and Protein Abbreviations
Protein

Human Gene

Mouse Gene

Endothelin 1

ET1

EDN1

Edn1

Endothelin 2

ET2

EDN2

Edn2

Endothelin 3

ET3

EDN3

Edn3

Endothelin A Type Receptor

EDNRA

EDNRA

Ednra

Endothelin B Type Receptor

EDNRB

EDNRB

Ednrb

Endothelin Converting Enzyme 1

ECE1

ECE1

Ece1

Endothelin Converting Enzyme 2

ECE2

ECE2

Ece2
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